


Express Mail Label No.: EV 392131467 US

Date of Deposit: October 7, 2004

Attorney Docket No.: 23239-558 A



10-08-04 IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Epstein, et al.
SERIAL NUMBER : 10/829,504 EXAMINER : Not Yet Assigned
FILING DATE : April 21, 2004 ART UNIT : 1632
FOR : STABILIZED APTAMERS TO PLATELET DERIVED GROWTH
FACTOR AND THEIR USE AS ONCOLOGY THERAPEUTICS

Mail Stop Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action based on the merits in the above-identified case. Accordingly, no fee or certification is believed required. By the waiver of 37 CFR 1.98(a)(2)(i) copies of the U.S. Patents A1-A37 are not submitted.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.


By submitting this Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

APPLICANTS: Epstein et al.
U.S.S.N.: 10/829,504

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 23239-558A.

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529
Jennifer A. Karnakis, Reg. No. 53,097
Attorneys for Applicants
c/o MINTZ, LEVIN
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241
Customer No. 30623

Date: October 7, 2004

TRA 1965314v1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Epstein, et al.
SERIAL NUMBER : 10/829,504 EXAMINER : Not Yet Assigned
FILING DATE : April 21, 2004 ART UNIT : 1632
FOR : STABILIZED APTAMERS TO PLATELET DERIVED GROWTH
FACTOR AND THEIR USE AS ONCOLOGY THERAPEUTICS

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:


1. Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (5 pages), in duplicate;
3. Copies of Cited References: B1-10; C1-103; and
4. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 23239-558A.

A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,



For R. Elrifi, Reg. No. 39,529
Jennifer A. Karnakis, Reg. No. 53,097
Attorneys for Applicants
c/o MINTZ, LEVIN
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241
Customer No. 30623

Date: October 7, 2004

Express Mail No.: EV 392157521 US
Date of Deposit: October 8, 2004

Page 1 of 5
Attorney Docket No.: 23239-558 A CIP

Please type a plus sign (+) in this box



| | | |
|--|-------------------------------|------------------|
| Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) | Application Number | 10/829,504 |
| | Filing Date | April 21, 2004 |
| | First Named Inventor | Epstein |
| | Group Art Unit | 1632 |
| | Examiner Name | Not Yet Assigned |
| | Attorney Docket Number | 23239-558A |

| U.S. PATENT DOCUMENTS | | | | | | | |
|-----------------------|----------|--------------------------|------------|-------------------------------------|-------|-----------|----------------------------|
| Exam Initials | Cite No. | U.S. Patent Document No. | Issue Date | Name of Patentee(s) or Applicant(s) | Class | Sub Class | Filing Date If Appropriate |
| | *A1 | 3,710,795 | 01/16/73 | Higuchi et al. | 128 | 260 | |
| | *A2 | 5,262,564 | 11/16/93 | Kun et al. | 562 | 430 | |
| | *A3 | 5,270,163 | 12/14/93 | Gold et al. | 435 | 6 | |
| | *A4 | 5,475,096 | 12/12/95 | Gold et al. | 536 | 23.1 | |
| | *A5 | 5,496,938 | 03/05/96 | Gold et al. | 536 | 22.1 | |
| | *A6 | 5,567,588 | 10/22/96 | Gold et al. | 435 | 6 | |
| | *A7 | 5,580,737 | 12/03/96 | Polisky et al. | 435 | 6 | |
| | *A8 | 5,589,332 | 12/31/96 | Shih et al. | 435 | 6 | |
| | *A9 | 5,637,459 | 06/10/97 | Burke et al. | 435 | 6 | |
| | *A10 | 5,648,214 | 07/15/97 | Nieuwlandt et al. | 435 | 6 | |
| | *A11 | 5,660,985 | 08/26/97 | Pieken et al. | 435 | 6 | |
| | *A12 | 5,668,264 | 09/16/97 | Janjic et al. | 536 | 23.1 | |
| | *A13 | 5,672,695 | 09/30/97 | Eckstein et al. | 536 | 24.5 | |
| | *A14 | 5,674,685 | 10/07/97 | Janjic et al. | 435 | 6 | |
| | *A15 | 5,674,980 | 10/07/97 | Frankel et al. | 530 | 350 | |
| | *A16 | 5,683,867 | 11/04/97 | Biesecker et al. | 435 | 6 | |
| | *A17 | 5,698,687 | 12/16/97 | Eckstein et al. | 536 | 25.3 | |
| | *A18 | 5,705,337 | 01/06/98 | Gold et al. | 435 | 6 | |
| | *A19 | 5,707,796 | 01/13/98 | Gold et al. | 435 | 6 | |
| | *A20 | 5,763,177 | 06/09/98 | Gold et al. | 435 | 6 | |
| | *A21 | 5,804,604 | 09/08/98 | Frankel et al. | 530 | 324 | |
| | *A22 | 5,817,635 | 10/06/98 | Eckstein et al. | 514 | 44 | |
| | *A23 | 5,834,186 | 11/10/98 | George et al. | 435 | 6 | |
| | *A24 | 5,859,228 | 01/12/99 | Janjic et al. | 536 | 24.3 | |
| | *A25 | 5,958,691 | 09/28/99 | Pieken et al. | 435 | 6 | |
| | *A26 | 6,011,020 | 01/04/00 | Gold et al. | 514 | 44 | |
| | *A27 | 6,051,698 | 04/18/00 | Janjic et al. | 536 | 24.31 | |
| | *A28 | 6,207,646 B1 | 03/27/01 | Krieg et al. | 514 | 44 | |
| | *A29 | 6,207,816 B1 | 03/27/01 | Gold et al. | 536 | 24.1 | |
| | *A30 | 6,214,806 B1 | 04/10/01 | Krieg et al. | 514 | 44 | |
| | *A31 | 6,229,002 B1 | 05/08/01 | Janjic et al. | 536 | 23.1 | |
| | *A32 | 6,239,116 B1 | 05/29/01 | Krieg et al. | 514 | 44 | |
| | *A33 | 6,426,434 B1 | 07/30/02 | Yoshida et al. | 564 | 71 | |
| | *A34 | 6,429,199 B1 | 08/06/02 | Krieg et al. | 514 | 44 | |

| U.S. PATENT DOCUMENTS | | | | | | | |
|-----------------------|----------|--------------------------|------------|-------------------------------------|-------|-----------|----------------------------|
| Exam Initials | Cite No. | U.S. Patent Document No. | Issue Date | Name of Patentee(s) or Applicant(s) | Class | Sub Class | Filing Date If Appropriate |
| | *A35 | 6,498,148 B1 | 12/24/02 | Raz | 514 | 44 | |
| | *A36 | 6,514,948 B1 | 02/04/03 | Raz et al. | 514 | 44 | |
| | *A37 | 6,653,292 B1 | 11/25/03 | Krieg et al. | 514 | 44 | |

| FOREIGN PATENT DOCUMENTS | | | | | | | |
|--------------------------|----------|--------------------------------|--------------|---|---------------------|-----------------|----|
| Exam Initials | Cite No. | Foreign Patent Document Office | Number | Name of Patentee(s) or Applicant(s) | Date of Publication | Translation Yes | No |
| | *B1 | WO | 91/19813 | The Univ. of Colorado Foundation, Inc. | 12/26/91 | | |
| | *B2 | WO | 92/07065 | Maxplanck-Gesellschaft Zur Förderung Der Wissenschaften | 04/30/92 | | |
| | *B3 | WO | 98/08974 | Intelligene Ltd. | 03/05/98 | | |
| | *B4 | WO | 98/18480 | Nexstar Pharmaceuticals, Inc. | 05/07/98 | | |
| | *B5 | WO | 98/27104 | Yale University | 06/25/98 | | |
| | *B6 | WO | 99/31276 | Nexstar Pharmaceuticals, Inc. | 06/24/99 | | |
| | *B7 | WO | 00/70329 | Brandeis University | 11/23/00 | | |
| | *B8 | WO | 01/66721 A2 | Ribozyme Pharmaceuticals, Inc. | 09/13/01 | | |
| | *B9 | WO | 02/22882 A2 | Archemix Corporation | 03/21/02 | | |
| | *B10 | WO | 03/014375 A2 | Archemix Corporation | 02/20/03 | | |

| OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS | | |
|---|----------|--|
| Exam Initials | Cite No. | Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc. |
| | *C1 | Agrawal et al. <i>Ciba Found. Symp.</i> , 209:60-75 (1997) |
| | *C2 | Akhtar et al. <i>Trends Pharmacol. Sci.</i> , 18:12-18 (1997) |
| | *C3 | Antopolsky et al. <i>Bioconjug. Chem.</i> , 10(4):598-606 (1999) |
| | *C4 | Astriab-Fisher et al. <i>Biochem. Pharmacol.</i> , 60(1):83-90 (2000) |
| | *C5 | Bell et al. <i>In Vitro Anim. Cell. Dev. Biol.</i> , 35(9):533-542 (1999) |
| | *C6 | Breaker R.R. <i>Curr. Opin. Biotech.</i> , 7:442-448 (1996) |
| | *C7 | Breaker R.R. <i>Chem. Rev.</i> , 97:371-390 (1997) |
| | *C8 | Breaker R.R. <i>Curr. Opin. Chem. Biol.</i> , 1:26-31 (1997) |
| | *C9 | Breaker R.R. <i>Nat. Biotech.</i> , 15:427-431 (1997) |
| | *C10 | Breaker R.R. <i>Intracellular Ribozyme Applications in Principles and Protocols</i> , pgs. 1-19; Horizon Scientific Press, Wymondham UK, Rossi and Couture, eds., (1999) |
| | *C11 | Breaker R.R. <i>Curr. Opin. Biotech.</i> , 13:31-39 (2002) |
| | *C12 | Carmi et al. <i>Chem. & Biol.</i> , 3:1039-1046 (1996) |
| | *C13 | Carrasquillo et al. <i>Invest. Ophthalmol. Vis. Sci.</i> , 44(1):290-299 (2003) |
| | *C14 | Chen et al. <i>Proc. Natl. Acad. Sci. USA</i> , 100(16):9226-9231 (2003) |
| | *C15 | Cotten et al. <i>Nucl. Acids Res.</i> , 19(10):2629-2635 (1991) |
| | *C16 | Crooke S.T. <i>Adv. Pharmacol.</i> , 40:1-49 (1997) |
| | *C17 | Daniels et al. <i>Anal. Biochem.</i> , 305(2):214-226 (2002) |
| | *C18 | De Rijk et al. <i>Nucl. Acids Res.</i> , 25(22):4679-4684 (1997) |
| | *C19 | Ellington et al. <i>Nature</i> , 346(6287):818-822 (1990) |
| | *C20 | Froehler et al. <i>Nucl. Acids Res.</i> , 14(13):5399-5407 (1986) |

| OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS | | |
|---|----------|--|
| Exam Initials | Cite No. | Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc. |
| | *C21 | Froehler et al. <i>Tet. Lett.</i> , 27(46):5575-5578 (1986) |
| | *C22 | Gold L. <i>Nat. Biotech.</i> , 20: 671-672 (2002) |
| | *C23 | Golub et al. <i>Cell</i> , 77(2):307-316 (1994) |
| | *C24 | Green et al. <i>Chem. Biol.</i> , 2:683-695 (1995) |
| | *C25 | Greenwald et al. <i>J. Org. Chem.</i> , 60:331-336 (1995) |
| | *C26 | Griffin et al. <i>Gene</i> , 137(1):25-31 (1993) |
| | *C27 | Grindel et al. <i>Antisense Nucl. Acid Drug Dev.</i> , 8(1):43-52 (1998) |
| | *C28 | Hamaguchi et al. <i>Anal. Biochem.</i> , 294:126-131 (2001) |
| | *C29 | Harris et al. <i>Nat. Rev. Drug Discov.</i> , 2(3):214-221 (2003) |
| | *C30 | Hartig et al. <i>Nat. Biotech.</i> , 20:717-722 (2002) |
| | *C31 | Heinreich et al. <i>Science</i> , 299(5607):708-710 (2003) |
| | *C32 | Hirose et al. <i>Tet. Lett.</i> , 28:2449-2452 (1978) |
| | *C33 | Hobbs et al. <i>Biochem.</i> , 12(25):5138-5145 (1973) |
| | *C34 | Jaeger et al. <i>Proc. Natl. Acad. Sci. USA</i> , 86:7706-7710 (1989) |
| | *C35 | Jain et al. <i>Cancer Res.</i> , 47(12):3039-3051 (1987) |
| | *C36 | Jain et al. <i>Adv. Drug Deliv.</i> , 26:71-90 (1997) |
| | *C37 | Jellinek et al. <i>Biochem.</i> , 34(36):11363-11372 (1995) |
| | *C38 | Jenison et al. <i>Antisense Nucl. Acid Drug Dev.</i> , 8(4):265-279 (1998) |
| | *C39 | Jenne et al. <i>Nat. Biotech.</i> , 19:56-61 (2001) |
| | *C40 | Khati et al. <i>J. Virol.</i> , 77(23):12692-12698 (2003) |
| | *C41 | Koizumi et al. <i>Nucl. Acids Symp. Ser.</i> , 42:275-276 (1999) |
| | *C42 | Koizumi et al. <i>Nat. Struct. Biol.</i> , 6(11):1062-1071 (1999) |
| | *C43 | Kraus et al. <i>J. Immunol.</i> , 160:5209-5212 (1998) |
| | *C44 | Krieg A.M. <i>Annu. Rev. Immunol.</i> , 20:709-760 (2002) |
| | *C45 | Lebedeva et al. <i>Eur. J. Pharm. Biopharm.</i> , 50(1):101-119 (2000) |
| | *C46 | Li et al. <i>Curr. Opin. Struct. Biol.</i> , 9:315-323 (1999) |
| | *C47 | Li et al. <i>Proc. Natl. Acad. Sci. USA</i> , 96:2746-2751 (1999) |
| | *C48 | Lin et al. <i>Nucl. Acids Res.</i> , 22(24):5529-5234 (1994) |
| | *C49 | Magnusson et al., <i>Blood</i> , 98(8):2518-2525 (2001) |
| | *C50 | Manoharan M. <i>Antisense Nucl. Acid Drug Dev.</i> , 12(2):103-128 (2002) |
| | *C51 | Marshall et al., <i>Nat. Struct. Biol.</i> , 6(11):992-994 (1999) |
| | *C52 | Mathews et al. <i>J. Mol. Biol.</i> , 288(5):911-940 (1999) |
| | *C53 | Monteith et al. <i>Toxicol. Pathol.</i> , 27(1):8-13 (1999) |
| | *C54 | O'Brien et al. <i>Genes Chromosomes & Cancer</i> , 23(2):187-193 (1998) |
| | *C55 | Ostman et al. <i>Adv. Cancer Res.</i> , 80:1-38 (2001) |
| | *C56 | Padilla et al. <i>Nucl. Acids Res.</i> , 30(24):e138 (2002) |
| | *C57 | Pagratitis et al. <i>Nat. Biotechnol.</i> , 15(1):68-73 (1997) |
| | *C58 | Peng et al. <i>Antisense Nucl. Acid Drug Dev.</i> , 11(1):15-27 (2001) |
| | *C59 | Pieken et al. <i>Science</i> , 253:314-317 (1991) |

| OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS | | |
|---|----------|---|
| Exam Initials | Cite No. | Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc. |
| | *C60 | Pietersz et al. <i>Vaccine</i> , 19(11-12):1397-1405 (2001) |
| | *C61 | Pietras et al. <i>Cancer Res.</i> , 61:2929-2934 (2001) |
| | *C62 | Pietras et al. <i>Cancer Res.</i> , 62:5476-5484 (2002) |
| | *C63 | Pietras et al. <i>Cancer Cell</i> , 3:439-443 (2003) |
| | *C64 | Potyrailo et al. <i>Anal. Chem.</i> , 70:3419-3425 (1998) |
| | *C65 | Reyderman et al. <i>Pharm. Res.</i> , 15(6):904-910 (1998) |
| | *C66 | Richardson et al. <i>Biochem. Pharmacol.</i> , 59(9):1045-1052 (2000) |
| | *C67 | Richardson et al. <i>Chem. Res. Toxicol.</i> , 15(7):922-926 (2002) |
| | *C68 | Robertson et al. <i>Nucl. Acids Res.</i> , 28(8):1751-1759 (2000) |
| | *C69 | Robertson et al. <i>Nat. Biotech.</i> , 17:62-66 (1999) |
| | *C70 | Robertson et al. <i>Nat. Biotech.</i> , 19:650-655 (2001) |
| | *C71 | Rothbard et al. <i>Nat. Med.</i> , 6(11):1253-1257 (2000) |
| | *C72 | Rothbard J. <i>J. Med. Chem.</i> , 45(17):3612-3618 (2002) |
| | *C73 | Ruckman et al. <i>J. Biol. Chem.</i> , 273(32):20556-20567 (1998) |
| | *C74 | Sassanfar et al. <i>Nature</i> , 364:550-553 (1993) |
| | *C75 | Seetharaman et al. <i>Nat. Biotech.</i> , 19:336-341 (2001) |
| | *C76 | Seiwert et al. <i>Chem. & Biol.</i> , 7:833-843 (2000) |
| | *C77 | Shimizui et al. <i>Cancer Res.</i> , 59:3719-3723 (1999) |
| | *C78 | Simon et al. <i>Nat. Genet.</i> , 15:95-98 (1997) |
| | *C79 | Smidt et al. <i>Nucl. Acids Res.</i> , 19(17):4695-4700 (1991) |
| | *C80 | Smith et al. <i>Cell</i> , 89(5):669-672 (1997) |
| | *C81 | Sood et al. <i>Nucl. Acids Res.</i> , 4(8):2757-2765 (1977) |
| | *C82 | Soukup et al. <i>Proc. Natl. Acad. Sci. USA</i> , 96:3584-3589 (1999) |
| | *C83 | Soukup et al. <i>RNA</i> , 5:1308-1325 (1999) |
| | *C84 | Soukup et al. <i>Structure</i> , 7(7):783-791 (1999) |
| | *C85 | Soukup et al. <i>Tren. Biotech.</i> , 17:469-476 (1999) |
| | *C86 | Soukup et al. in <i>Ribozyme Biochem. Biotech.</i> , Eaton Publishing, Chapter 8, pgs. 149-170, Krupp & Gaur, eds. (2000) |
| | *C87 | Soukup et al. <i>RNA</i> , 7:524-536 (2001) |
| | *C88 | Soukup et al. <i>J. Mol. Biol.</i> , 298:623-632 (2000) |
| | *C89 | Sproat et al. <i>Nucl. Acids Res.</i> , 19(4):733-738 (1991) |
| | *C90 | Srinivasan et al. <i>J. Clin. Lab. Anal.</i> , 9(2):129-137 (1995) |
| | *C91 | Tang et al. <i>Chem. & Biol.</i> , 4:453-459 (1997) |
| | *C92 | Tang et al. <i>Nucl. Acids Res.</i> , 26(18):4214-4221 (1998) |
| | *C93 | Tang et al. <i>RNA</i> , 3:914-925 (1997) |
| | *C94 | Tavitian et al. <i>Nat. Med.</i> , 4(4):467-471 (1998) |
| | *C95 | Tucker et al. <i>J. Chromatography B</i> , 732:203-212 (1999) |
| | *C96 | Tuerk et al. <i>Science</i> , 249(4968):505-510 (1990) |
| | *C97 | Uhlmann et al. <i>Methods Enzymol.</i> , 313:268-284 (2000) |
| | *C98 | Vaish et al. <i>Biochem.</i> , 42(29):8842-8851 (2003) |

Date of Deposit: October 8, 2004

Attorney Docket No.: 23239-558 A CIP

| OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS | | |
|---|----------|--|
| Exam Initials | Cite No. | Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc. |
| | *C99 | Vives et al. <i>J. Biol. Chem.</i> , 272(25):16010-16017 (1997) |
| | *C100 | Watson et al. <i>Antisense Nucl. Acid Drug Dev.</i> , 10(2):63-75 (2000) |
| | *C101 | Wlotzka et al. <i>Proc. Natl. Acad. Sci. USA</i> , 99(13):8898-8902 (2002) |
| | *C102 | Zubin et al. <i>FEBS Lett.</i> , 456(1):59-62 (1999) |
| | *C103 | Zuker M. <i>Science</i> , 244:48-52 (1989) |

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 10/829,504, filed April 21, 2004 , and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

TRA 1965293v1